The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer

Cancer Letters

Volumn 325, Issue 1, 2012, Pages 35-41

  Roh, Jong Lyel ^a   Ko, Jung Ho ^a   Moon, Soo Jin ^a   Ryu, Chang Hwan ^a   Choi, Jun Young ^a   Koch, Wayne M ^b  

^a University of Ulsan College of Medicine   (South Korea)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Head and neck cancer; P53; Reactivation; RITA

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CISPLATIN; PIFITHRIN ALPHA; PROTEIN BAX; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; REACTIVATION OF P53 AND INDUCTION OF TUMOR CELL APOPTOSIS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME DEGRADATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; UPREGULATION; WILD TYPE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BENZOTHIAZOLES; CASPASE 3; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG SYNERGISM; FURANS; G2 PHASE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-MDM2; TOLUENE; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865285462     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.05.020     Document Type: Article

References (38)

1. Boyle P., Levin B. World cancer report 2008. The International Agency for Research on Cancer 2008, 330-338. WHO Press, Geneva, Switzerland.
2. Argiris A., Eng C. Epidemiology, staging, and screening of head and neck cancer. Cancer Treat. Res. 2003, 114:15-60.
3. Marur S., D'Souza G., Westra W.H., Forastiere A.A. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010, 11:781-789.
4. Haddad R.I., Shin D.M. Recent advances in head and neck cancer. N. Engl. J. Med. 2008, 359:1143-1154.
5. Argiris A., Karamouzis M.V., Raben D., Ferris R.L. Head and neck cancer. Lancet 2008, 371:1695-1709.
6. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10:789-799.
7. Mandic R., Schamberger C.J., Müller J.F., Geyer M., Zhu L., Carey T.E., Grénman R., Dünne A.A., Werner J.A. Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53. Clin. Cancer Res. 2005, 11:6845-6852.
8. Sen T., Sen N., Brait M., Begum S., Chatterjee A., Hoque M.O., Ratovitski E., Sidransky D. DeltaNp63alpha confers tumor cell resistance to cisplatin through the AKT1 transcriptional regulation. Cancer Res. 2011, 71:1167-1176.
9. Partridge M., Costea D.E., Huang X. The changing face of p53 in head and neck cancer. Int. J. Oral Maxillofac. Surg. 2007, 36:1123-1138.
10. Brown C.J., Lain S., Verma C.S., Fersht A.R., Lane D.P. Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 2009, 9:862-873.
11. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356:215-221.
12. Malkin D., Li F.P., Strong L.C., Fraumeni J.F., Nelson C.E., Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250:1233-1238.
13. Bunz F., Hwang P.M., Torrance C., Waldman T., Zhang Y., Dillehay L., Williams J., Lengauer C., Kinzler K.W., Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 1999, 104:263-269.
14. Poeta M.L., Manola J., Goldwasser M.A., Forastiere A., Benoit N., Califano J.A., Ridge J.A., Goodwin J., Kenady D., Saunders J., Westra W., Sidransky D., Koch W.M. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 2007, 357:2552-2561.
15. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2002, 2:594-604.
16. Selivanova G., Wiman K.G. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 2007, 26:2243-2254.
17. Martins C.P., Brown-Swigart L., Evan G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006, 127:1323-1334.
18. Selivanova G. Therapeutic targeting of p53 by small molecules. Semin. Cancer Biol. 2010, 20:46-56.
19. Cheok C.F., Verma C.S., Baselga J., Lane D.P. Translating p53 into the clinic. Nat. Rev. Clin. Oncol. 2011, 8:25-37.
20. Shangary S., Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin. Cancer Res. 2008, 14:5318-5324.
21. Arya A.K., El-Fert A., Devling T., Eccles R.M., Aslam M.A., Rubbi C.P., Vlatković N., Fenwick J., Lloyd B.H., Sibson D.R., Jones T.M., Boyd M.T. Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53. Br. J. Cancer 2010, 103:186-195.
22. Roh J.L., Kang S.K., Minn I., Califano J.A., Sidransky D., Koch W.M. P53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Oral Oncol. 2011, 47:8-15.
23. Issaeva N., Bozko P., Enge M., Protopopova M., Verhoef L.G., Masucci M., Pramanik A., Selivanova G. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 2004, 10:1321-1328.
24. Enge M., Bao W., Hedström E., Jackson S.P., Moumen A., Selivanova G. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 2009, 15:171-183.
25. Kim S.Y., Chu K.C., Lee H.R., Lee K.S., Carey T.E. Establishment and characterization of nine new head and neck cancer cell lines. Acta Otolaryngol. 1997, 117:775-784.
26. Miyachi M., Kakazu N., Yagyu S., Katsumi Y., Tsubai-Shimizu S., Kikuchi K., Tsuchiya K., Iehara T., Hosoi H. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Clin. Cancer Res. 2009, 15:4077-4084.
27. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔ C(T)) method. Method 2001, 25:402-408.
28. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
29. Nahi H., Selivanova G., Lehmann S., Möllgård L., Bengtzen S., Concha H., Svensson A., Wiman K.G., Merup M., Paul C. Mutated and non-mutated TP53 as targets in the treatment of leukaemia. Br. J. Haematol. 2008, 141:445-453.
30. Grinkevich V.V., Nikulenkov F., Shi Y., Enge M., Bao W., Maljukova A., Gluch A., Kel A., Sangfelt O., Selivanova G. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 2009, 15:441-453.
31. Zhao C.Y., Szekely L., Bao W., Selivanova G. Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. Cancer Res. 2010, 70:3372-3381.
32. Chipuk J.E., Kuwana T., Bouchier-Hayes L., Droin N.M., Newmeyer D.D., Schuler M., Green S.R. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004, 303:1010-1014.
33. Rinaldo C., Prodosmo A., Siepi F., Moncada A., Sacchi A., Selivanova G., Soddu S. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA. Cancer Res. 2009, 69:6241-6248.
34. Zhao C.Y., Grinkevich V.V., Nikulenkov F., Bao W., Selivanova G. Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA. Cell Cycle 2010, 9:1847-1855.
35. Spinnter C., Hedström E., Li H., de Lange J., Nikulenkov F., Teunisse A.F., Verlaan-de Varies M., Grinkevich V., Jochemsen A.G. Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX. Cell Death Diff. 2011, 18:1736-1745.
36. Drakos E., Atsaves V., Schlette E., Li J., Papanastasi I., Rassidakis G.Z., Medeiros L.J. The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53. Leukemia 2009, 23:2290-2299.
37. Bykov V.J., Zache N., Stridh H., Westman J., Bergman J., Selivanova G., Wiman K.G. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 2005, 24:3484-3491.
38. Magrini R., Russo D., Ottaggio L., Fronza G., Inga A., Menichini P. PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells. J. Cell Biochem. 2008, 104:2363-2373.